Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.